Buy Zydus Lifesciences; target of Rs 1268: Sharekhan

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1268 in its research report dated October 03, 2024.

Broker Research

October 04, 2024 / 14:02 IST

Buy

26 Aug, 2025 12:21

Volume

Todays L/H

Sharekhan's research report on Zydus Lifesciences

Zydus Lifesciences Ltd has partnered with the Central Drug Research Institute (CDRI) to develop an oral treatment for osteoporosis related to chronic kidney disease (CKD) and postmenopausal conditions, focusing on small-molecule inhibitors of the protein sclerostin. The company has launched a Phase-1 trial for the ZY19489-Ferroquine combination, now actively recruiting 36 patients to assess safety, tolerability, and pharmacokinetics, with a projected completion date of February 1, 2025. Zydus has received a tentative approval from the USFDA to manufacture Enzalutamide Tablets for prostate cancer treatment, with production set to occur at its SEZ facility in Ahmedabad; these tablets generated annual sales of approximately $1.42 billion in the US as of July 2024.

Outlook

Maintain Buy with a revised PT of Rs. 1,268: Zydus Lifesciences Ltd. is well-positioned for significant growth, supported by its strategic partnerships and active clinical programs. Collaboration with the CDRI to develop an oral treatment for osteoporosis associated with chronic kidney disease (CKD) targets a critical healthcare need, potentially addressing the concerns of over 10% of the global CKD population.

For all recommendations report, click here